Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | MEDI3726 |
| Synonyms | |
| Therapy Description |
MEDI3726 (ADCT-401) is an antibody-drug conjugate consisting of a monoclonal antibody that targets prostate specific membrane antigen and the cytotoxic agent, pyrrolobenzodiazepine (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3111A, PMID: 32459957, PMID: 30065100). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| MEDI3726 | ADCT-401|ADCT401|MEDI-3726|MEDI 3726 | PSMA Antibody 22 | MEDI3726 (ADCT-401) is an antibody-drug conjugate consisting of a monoclonal antibody that targets prostate specific membrane antigen and the cytotoxic agent, pyrrolobenzodiazepine (AACR; Cancer Res 2017;77(13 Suppl):Abstract nr 3111A, PMID: 32459957, PMID: 30065100). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT02991911 | Phase I | Enzalutamide + MEDI3726 MEDI3726 | A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer | Completed | USA | GBR | CHE | 0 |